Drugs /

temuterkib

Back to Drugs List
Associated Genetic Biomarkers

Overview

NCI Definition [1]:
An orally available inhibitor of extracellular signal-regulated kinase (ERK) 1 and 2, with potential antineoplastic activity. Upon oral administration, LY3214996 inhibits both ERK 1 and 2, thereby preventing the activation of mitogen-activated protein kinase (MAPK)/ERK-mediated signal transduction pathways. This results in the inhibition of ERK-dependent tumor cell proliferation and survival. The MAPK/ERK pathway is often upregulated in a variety of tumor cell types and plays a key role in tumor cell proliferation, differentiation and survival.

Clinical Trials

View Clinical Trials for temuterkib

Temuterkib has been investigated in 7 clinical trials, of which 6 are open and 1 is closed. Of the trials investigating temuterkib, 1 is early phase 1 (1 open), 3 are phase 1 (2 open), 1 is phase 1/phase 2 (1 open), and 2 are phase 2 (2 open).

BRAF Mutation, BRAF Fusion, and BRAF V600E are the most frequent biomarker inclusion criteria for temuterkib clinical trials.

Acute myeloid leukemia, cancer, and chronic lymphocytic leukemia are the most common diseases being investigated in temuterkib clinical trials [2].

Top Biomarker Inclusion Criteria for Open Clinical Trials Investigating Temuterkib
Top Biomarker Inclusion Criteria for Closed Clinical Trials Investigating Temuterkib
This graph displays the 20 most frequently occurring biomarkers curated on clinical trials investigating temuterkib and the cancer types associated with these biomarkers. These numbers are derived from a set of 5,956 clinical trials for which biomarker status defines treatment.

Drug Details

Synonyms [2]:
erk1/2 inhibitor ly3214996, ly3214996, ly 3214996, temuterkib, ly-3214996
Drug Categories [2]:
ERK inhibitor, Serine/threonine kinase inhibitors
Drug Target(s) [2]:
MAPK1, MAPK3
NCIT ID [1]:
C131335

References

1. National Cancer Institute. NCI Thesaurus Version 18.11d. https://ncit.nci.nih.gov/ncitbrowser/. [2018-07-30] [2018-08-02].

2. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.